Suppr超能文献

急性冠状动脉综合征后双联抗血小板治疗停药的临床影响的系统评价。

Systematic review of the clinical impact of dual antiplatelet therapy discontinuation after acute coronary syndromes.

机构信息

1 Klinikum Ludwigshafen, Institut für Herzinfarktforschung, Germany.

2 Research and Evaluation Unit, Oxford PharmaGenesis Ltd, UK.

出版信息

Eur Heart J Acute Cardiovasc Care. 2017 Sep;6(6):522-531. doi: 10.1177/2048872616648467. Epub 2016 May 3.

Abstract

AIMS

The aim of this systematic literature review was to assess the consequences of dual antiplatelet therapy discontinuation on clinical outcomes after acute coronary syndromes.

METHODS AND RESULTS

A systematic literature search was conducted in PubMed to identify studies reporting data on patients who discontinued dual antiplatelet therapy (planned or unplanned) following acute coronary syndromes and on the clinical impact of dual antiplatelet therapy discontinuation. To be included, more than 50% of the study population had to have had acute coronary syndrome as their index event or, if less than 50%, outcomes data must have been reported separately for the group with acute coronary syndromes. Thirty publications covering 29 studies were identified for inclusion. There was much heterogeneity across studies regarding the included patient populations, treatment durations and outcome definitions and ascertainments. Dual antiplatelet therapy discontinuation was most commonly based on physician decision. Twenty-six studies reported that clopidogrel was prescribed as part of dual antiplatelet therapy. Dual antiplatelet therapy duration was positively associated with a lower risk of all-cause mortality (seven/eight studies), cardiovascular mortality (two/two studies), non-fatal myocardial infarction (two/three studies) and stent thrombosis (five/five studies) in patients and/or patient subgroups in studies without randomised treatment designs, although such associations were not observed in the one study that randomly assigned patients to treatment (i.e. planned discontinuation).

CONCLUSIONS

Results from our systematic literature review generally support the benefit of longer-term dual antiplatelet therapy after acute coronary syndromes; however, further research is needed to determine the optimal length of dual antiplatelet therapy in patients after acute coronary syndrome, ideally using prospective studies.

摘要

目的

本系统文献回顾的目的是评估急性冠脉综合征后停用双联抗血小板治疗对临床结局的影响。

方法和结果

在 PubMed 中进行了系统文献检索,以确定报告了以下数据的研究:在急性冠脉综合征后停止双联抗血小板治疗(计划或非计划)的患者,以及双联抗血小板治疗停药的临床影响。为了被纳入,研究人群中必须有超过 50%的人发生急性冠脉综合征作为其首发事件,或者如果少于 50%,则必须分别报告有急性冠脉综合征的患者组的结局数据。确定了 30 篇涵盖 29 项研究的文献纳入本研究。关于纳入的患者人群、治疗持续时间和结局定义和确定,研究之间存在很大的异质性。双联抗血小板治疗停药最常见的是基于医生的决定。26 项研究报告氯吡格雷被作为双联抗血小板治疗的一部分。在没有随机治疗设计的研究中,双联抗血小板治疗持续时间与全因死亡率(7/8 项研究)、心血管死亡率(2/2 项研究)、非致死性心肌梗死(2/3 项研究)和支架血栓形成(5/5 项研究)的风险降低呈正相关,在一项对患者进行随机分组治疗的研究(即计划停药)中未观察到这种关联。

结论

我们的系统文献回顾结果总体上支持急性冠脉综合征后长期双联抗血小板治疗的益处;然而,需要进一步的研究来确定急性冠脉综合征后患者双联抗血小板治疗的最佳持续时间,理想情况下使用前瞻性研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验